摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4aS,4bR,6aS,8S,10aS,10bS,12aS)-8-羟基-10a,12a-二甲基-3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十四氢-1H-萘并[2,1-f]喹啉-2-酮 | 39932-99-5

中文名称
(4aS,4bR,6aS,8S,10aS,10bS,12aS)-8-羟基-10a,12a-二甲基-3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十四氢-1H-萘并[2,1-f]喹啉-2-酮
中文别名
——
英文名称
3β-hydroxy-13α-amino-13,17-seco-5α-androstan-17-oic-13,17-lactam
英文别名
17a-aza-D-homo-5α-androstan-3β-ol-17-one;3β-hydroxy-17a-aza-D-homo-5α-androstan-17-one;3β-Hydroxy-17a-aza-D-homo-5α-androstan-17-on;3beta-Hydroxy-13alpha-amino-13,17-seco-5alpha-androstan-17-oic-13,17-lactam;(4aS,4bR,6aS,8S,10aS,10bS,12aS)-8-hydroxy-10a,12a-dimethyl-3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-tetradecahydro-1H-naphtho[2,1-f]quinolin-2-one
(4aS,4bR,6aS,8S,10aS,10bS,12aS)-8-羟基-10a,12a-二甲基-3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十四氢-1H-萘并[2,1-f]喹啉-2-酮化学式
CAS
39932-99-5
化学式
C19H31NO2
mdl
——
分子量
305.461
InChiKey
RVLMBTDFEBZGMJ-BECBKZTQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    22
  • 可旋转键数:
    0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.95
  • 拓扑面积:
    49.3
  • 氢给体数:
    2
  • 氢受体数:
    2

SDS

SDS:289ad9b8ffa3353061a7499b81dc876e
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • On the formation of homo-azasteroidal esters of<i>N,N</i>-bis(2-chloroethyl)aminobenzoic acid isomers and their antitumor activity
    作者:A. Anastasiou、P. Catsoulacos、A. Papageorgiou、E. Margariti
    DOI:10.1002/jhet.5570310219
    日期:1994.3
    (BHK) in vitro. The esters in which the alkylating congener is linked to the lactam alcohol in the axial position are inactive in vivo in P388 leukemia, while compounds 1, 4, 6, 13, 14 and the alkylating congeners 17, 18 and 20 are active. The effect of the homo-azasteroidal of N, N-bis(2-chloroethyl)aminobenzoic acid isomers and of 4-methyl-3-N, N-bis(2-chloroethyl)aminobenzoic acid on the incorporation
    3 , β-羟基-13α-氨基-13,17-seco-5α的N,N-双(2-氯乙基)氨基苯甲酸酯异构体和4-甲基-3 - N,N-双(2-氯乙基)氨基苯甲酸酯-androstan-17-oic-13,17-内酰胺,3α-羟基-13α-氨基-13,17-seco-5α-androstan-17-oic-13,17-内酰胺,3α-羟基-13α-氨基-13制备了1,17-seco-5-androsten-17-oic-13,17-内酰胺和17β-羟基-3-氮杂-A-homo-4α-androsten-4-one,并评估了其对P388白血病的生物学活性体内和艾氏腹水肿瘤(EAT),P388和L1210白血病以及体外婴儿仓鼠细胞(BHK)。在P388白血病中,烷基化同源物在轴向位置与内酰胺醇连接的酯在体内无活性,而化合物1,4,6,13,14和所述烷基化同类物17,18和20是活动的。N,N-双(2
  • Structure-Anticancer and Structure-Genetic Activity Relationships of Homo-aza-steroidal Esters of N,N-Bis(2-chloroethyl)aminocinnamic Acid Isomers
    作者:P. Catsoulacos、Ch. Camoutsis、A. Papageorgiou、E. Margariti、K. Psarakl、D. Demopoulos
    DOI:10.1002/jps.2600820218
    日期:1993.2
    p-dimethylaminopyridine and dicyclohexylcarbodiimide as dehydrating agent. The esters were obtained in pure form after column chromatography, and their structures were verified and confirmed by analytical methods (IR and UV spectra). The 12 esters were tested in vivo against P388, L1210 leukemias, Ehrlich ascites tumor, and melanoma B16. The esters 3 alpha-hydroxy-13 alpha-amino-13,17-seco-5 alpha-androstan-17-
    A-环和D-环的四个甾族内酰胺分别在其核的C-3或C-17位置与N,N-双(2-氯乙基)氨基肉桂酸异构体进行酯化反应。在催化剂对二甲氨基吡啶和二环己基碳二亚胺作为脱水剂的存在下,在二氯甲烷中进行甾族内酰胺的羟基与每个芥末的缩合反应。柱层析后以纯净形式获得酯,并通过分析方法(红外和紫外光谱)验证和确认它们的结构。在体内测试了这12种酯类药物对P388,L1210白血病,艾氏腹水和黑色素瘤B16的抵抗力。酯3 alpha-hydroxy-13 alpha-amino-13,17-seco-5 alpha-androstan-17-oic-13,17-lactam-o,m,pN,N-bis(2-chloroethyl)aminocinnamates,在上述实验动物肿瘤系统中,其中烷基化剂在轴向位置与修饰的类固醇相连的化合物是无活性的。N,N-双(2-氯乙基)氨基肉桂酸异构体的均氮氮类固醇酯对放射
  • Evaluation and characterization of micronuclei induced by the antitumour agent ASE [3beta-hydroxy-13alpha-amino-13,17-seco-5alpha-androstan-17-oic-13,17-lactam-p-bis(2-chloroethyl)amino phenylacetate] in human lymphocyte cultures
    作者:C. Andrianopoulos
    DOI:10.1093/mutage/15.3.215
    日期:2000.5.1
    3β - Hydroxy - 13α - amino - 13, 17 - seco - 5α - androstan - 17 -oic-13,17-lactam-p-bis(2-chloroethyl)amino phenylacetate (ASE) is a homo-aza-steroidal ester of p-bis(2-chloroethyl) amino phenyl acetic acid and has been shown to display antineoplastic, mutagenic and genotoxic activity. In the present study an effort has been made to evaluate the ability of ASE to induce micronuclei (MN) in human lymphocytes treated in vitro using the cytokinesis-block assay. Lympocytes were treated with different concentrations of ASE (0.1, 0.25, 0.5, 1, 2.5, 5, 10 and 20 μg/ml) at two different cell culture times, 21 and 41 h after culture initiation. ASE treatment lasted until cell harvest, for 51 and 31 h, respectively. Two types of cultures were used, whole blood and isolated lymphocyte cultures. The content of induced MN was identified by FISH analysis, using an α-satellite DNA probe, in binucleate cells. Our results suggest that ASE is capable of increasing MN frequencies in human lymphocytes under both culture conditions. This increase is related to the concentration in a linear dose-dependent manner and is also dependent on the duration of treatment. FISH analysis has shown that the induced MN resulted mainly from breakage events. Additionally, a weak aneugenic effect was found at the higher concentrations in whole blood cultures as well as in isolated lymphocyte cultures. Cytotoxic effects of ASE were observed under both cell culture conditions with a linear dose-dependent relationship according to CBPI evaluation and were more pronounced in isolated lymphocyte cultures.
    3β-羟基-13α-氨基-13,17-仲-5α-雄甾烷-17-酸-13,17-内酰胺-对-双(2-氯乙基)氨基苯乙酸(ASE)是一种对-双(2-氯乙基)氨基苯乙酸的均氮甾醇酯,已被证明具有抗肿瘤、诱变和遗传毒性活性。在本研究中,我们使用细胞分裂受阻试验来评估 ASE 在体外处理的人类淋巴细胞中诱导微核(MN)的能力。在两个不同的细胞培养时间(培养开始后 21 和 41 小时),用不同浓度的 ASE(0.1、0.25、0.5、1、2.5、5、10 和 20 μg/ml)处理淋巴细胞。ASE 处理分别持续 51 小时和 31 小时直至细胞收获。使用了两种培养物:全血培养物和分离的淋巴细胞培养物。通过使用α-卫星DNA探针对双核细胞进行FISH分析,确定了诱导MN的含量。我们的结果表明,在这两种培养条件下,ASE 都能增加人类淋巴细胞中的 MN 频率。这种增加与浓度呈线性剂量依赖关系,也与处理时间长短有关。FISH 分析表明,诱导的 MN 主要来自断裂事件。此外,在较高浓度的全血培养物和分离的淋巴细胞培养物中发现了微弱的非遗传效应。根据 CBPI 评估结果,在这两种细胞培养条件下都观察到了 ASE 的细胞毒性效应,且与剂量呈线性依赖关系,在离体淋巴细胞培养中更为明显。
  • Edge, Graham J.; Imam, Syed H.; Marples, Brian A., Journal of the Chemical Society. Perkin transactions I, 1984, p. 2319 - 2326
    作者:Edge, Graham J.、Imam, Syed H.、Marples, Brian A.
    DOI:——
    日期:——
  • Profilis; Catsoulacos, European Journal of Medicinal Chemistry, 1983, vol. 18, # 6, p. 567 - 568
    作者:Profilis、Catsoulacos
    DOI:——
    日期:——
查看更多

同类化合物

锯齿石松宁 箭毒蛙毒素 C 坎库碘铵 十氢喹啉 十氢-2-甲基喹啉 八氢对苯二酚-4(1H)-酮 八氢喹啉-2(1H)-酮 八氢-2,6-喹啉二酮 [(4aS,4bR,6aS,8S,10aS,10bS,12aS)-10a,12a-二甲基-1,2,3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十六氢萘并[6,5-f]喹啉-8-基]2-[4-[二(2-氯乙基)氨基]苯基]乙酸酯 [(4aS,4bR,6aS,8S,10aS,10bS,12aS)-1,10a,12a-三甲基-2-氧代-3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十四氢萘并[6,5-f]喹啉-8-基]2-[4-[二(2-氯乙基)氨基]苯基]乙酸酯 8H-13,3,6a-乙基亚基-7,10-亚甲基噁庚并[3,4-i]-1-苯并吖辛因-8-酮,1-乙基十四氢-12a-羟基-6-甲氧基-3-甲基-,(3R,6S,6aS,7R,7aS,10S,12aS,13S,13aR,15R)-(9CI) 8-羟基-十氢喹啉 4-乙炔基-2-甲基十氢喹啉-4-醇 3-羟基-13,17-开环-5-雄甾烯-17-酸-13,17-内酰胺(4-(二(2-氯乙基)氨基)苯基)丁酸酯 2,5-二丙基十氢喹啉 1-(3-氯-丙基)-十氢-喹啉 1,2,2-三甲基-八氢-喹啉-4-酮 (4aS,4bR,8S,10aR,10bS,12aS)-10a,12a-二甲基-2-羰基-1,2,3,4,4a,4b,5,7,8,9,10,10a,10b,11,12,12a-十六氢萘并[2,1-f]喹啉-8-基{4-[二(2-氯乙基)氨基]苯基}乙酸酯 (4aS,4bR,6aS,8S,10aS,10bS,12aS)-8-羟基-10a,12a-二甲基-3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十四氢-1H-萘并[2,1-f]喹啉-2-酮 (3S,13R)-1,2,3,4,4aalpha,5,11,11aalpha-八氢-2,2,5-三甲基-3beta,5beta-乙桥-10bH-吡啶并[3,2-b]咔唑-10bbeta,13-二醇 (3R,6S,6aS,7R,7aS,10S,12aS,13R,13aR,14S,15R)-1-乙基十四氢-12a,14-二羟基-6-甲氧基-3-甲基-8H-13,3,6a-亚乙基-7,10-甲桥氧杂卓并[3,4-i]-1-苯并氮杂环辛四烯-8-酮 (2S,4aR,8aR)-2-甲基八氢-4(1H)-喹啉酮 (2R,4R,4As,8As)-rel-4-乙炔基十氢-1,2-二甲基-4-喹啉醇 (4aS,5R,8aR)-1-(tert-butoxy)carbonyl-2-oxo-5-(triisopropylsilyloxymethyl)decahydroquinoline trans-(+/-)-1-n-propyl-7-oxodecahydroquinoline 3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aβH)-benzo[c]quinolizin-3-one 3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aαH)-benzo[c]quinolizin-3-one 3,4,4a,5,6,7,8-heptahydro-8a-hydrodioxy-2(1H)-quinolinone [2-(2,3-dichloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone (octahydro-quinolin-1-yl)-(2-pyridin-3-yl-thiazol-4-yl)-methanone 2-methylperhydrothiazolo<2,3-j>quinoline 2,4-dichloro-N-[5-((4aRS,8aSR)-octahydroquinoline-1-carbonyl)pyridin-2-yl]benzamide (4aR*,5S*,8aR*)-1,2,3,4,4a,5,6,7,8,8a-Decahydro-5-<(dimethylphenylsilyl)methyl>-1-methylquinoline (4aS*,5S*,8aR*)-1,2,3,4,4a,5,6,7,8,8a-Decahydro-5-<(dimethylphenylsilyl)methyl>-1-(methoxycarbonyl)quinoline (2S,3R,4aS,5R,8aR)-1-(tert-butoxy)carbonyl-3-hydroxy-2-methyl-5-(triisopropylsilyloxymethyl)decahydroquinoline (+/-)-(2SR,4aRS,8aRS)-1-tert-butyloxycarbonyl-5-methylene-2-propyldecahydroquinoline (+/-)-(2SR,4aRS,8aRS)-1-tert-butyloxycarbonyl-2-propyldecahydroquinolin-5-one cis-4-[4-(octahydro-quinoline-1(2H)-ylcarbonyl)-thiophen-2-yl]-piperidine-1-carboxylic acid amide lepadin E (+)-lepadin D cis-(octahydro-quinolin-1(2H)-yl)-(5-piperidin-4-yl-thiophen-3-yl)-methanone 4-methyl-6-(3-methyl-2-thienyl)-4,5,6,7-tetrahydroquinolin-5-one 2,2,4,8-tetramethyldecahydroquinoline 10-oxo-2,5;5,9-diseco-A-dinor-strychnidine-2,5-dioic acid strychnidine-2,3,10-trione 3-tetrazolo-17a-aza-D-homo-3,5-androstadien-17-one 17a-methyl-3-tetrazolo-17a-aza-D-homo-3,5-androstadien-17-one methyl 4-oxooctahydroquinoline-1(2H)-carboxylate decahydro-2-oxo-8-quinolinepropanoic acid ethyl ester 1-octahydro[1]quinolyl-propan-2-ol